march
htn
preval
increas
parallel
age
pattern
may
repres
expect
preval
given
age
group
therefor
although
number
fatal
posit
patient
treat
acei
twice
number
treat
arb
one
definit
conclud
risk
benefit
therapi
due
confound
variabl
age
htn
well
impact
yet
unidentifi
comorbid
outcom
pandem
recent
studi
potenti
drug
target
evalu
author
report
arb
eg
irbesartan
may
associ
human
coronavirusesassoci
host
protein
human
interactom
irbesartan
target
gene
solut
carrier
famili
member
interact
gene
potenti
transcript
repressor
interact
nonstructur
protein
sarscov
particip
cov
replic
fidel
crackow
cowork
report
disrupt
result
increas
ang
ii
level
impair
cardiac
function
wherea
author
show
overexpress
reduc
left
ventricular
hypertrophi
myocardi
fibrosi
htn
rat
deshotel
et
al
investig
compensatori
reduct
express
activ
respons
ang
iimedi
htn
elev
level
ang
ii
decreas
activ
cell
surfac
via
rdepend
intern
mechan
moreov
vitro
treatment
cell
ang
ii
enhanc
ubiquitin
also
mediat
r
ultim
stimul
lysosom
degrad
might
prevent
interact
catalyt
site
report
prevent
r
antagonist
losartan
may
block
intern
proteolyt
degrad
ubiquitin
latter
pathway
repres
anoth
mechan
acei
arb
could
prevent
viral
entri
viral
protein
interact
reduc
presenc
stabil
r
complex
arb
could
prove
benefici
stabil
r
interact
prevent
viral
interact
intern
base
mechan
action
gurwitz
recent
suggest
arb
losartan
telmisartan
tent
therapi
patient
prior
develop
aliacut
respiratori
failur
howev
remain
unknown
whether
prevent
intern
would
effect
attenu
infect
sar
coronavirus
studi
urgent
need
clarifi
mechan
interestingli
liu
et
al
report
serum
ang
ii
level
significantli
higher
infect
noninfect
individu
linearli
associ
viral
load
lung
damag
suspect
ang
ii
via
pulmonari
vasoconstrict
lead
decreas
flow
ventilationperfus
mismatch
via
increas
vascular
permeabl
proinflammatori
prooxid
properti
may
induc
perpetu
ard
varieti
patholog
find
liu
et
al
would
support
hypothesi
elev
level
ang
ii
may
foster
ard
patient
nevertheless
studi
import
limit
perform
limit
sampl
requir
confirm
role
raa
peptid
acut
lung
injuri
also
investig
ard
patient
diagnos
within
hour
use
target
metabolom
approach
ang
concentr
significantli
higher
nonsurvivor
studi
entri
hour
ard
surviv
associ
lower
ang
level
higher
ang
concentr
precursor
ang
significantli
higher
averag
ang
ang
ratio
suggest
activ
higher
survivor
nonsurvivor
therefor
activ
seem
reduc
patient
succumb
ard
downstream
high
level
ang
ii
may
due
attenu
potenti
caus
interact
stimul
increas
product
aldosteron
aldosteron
turn
increas
ace
activ
induc
product
ang
ii
lead
potenti
viciou
cycl
perpetu
ard
moreov
aldosteron
decreas
express
masr
minim
antagon
benefit
ang
produc
aldosteron
receptor
blocker
aldosteron
synthas
inhibitor
may
potenti
role
therapi
howev
care
evalu
influenc
corticosteroid
synthesi
signal
requir
sinc
invad
alveolar
epitheli
cell
respiratori
symptom
often
common
report
report
sever
patient
cvd
might
associ
higher
level
suggest
increas
patient
maintain
raa
inhibitor
howev
studi
conduct
rat
xudong
et
al
express
dramat
decreas
age
gender
older
male
rat
also
lower
concentr
older
femal
rat
whether
alter
profil
similarli
observ
human
express
alter
diseas
requir
investig
also
recent
demonstr
recombin
administr
mice
ard
protect
develop
ali
sever
lung
diseas
thu
strongli
suggest
mediat
cytoprotect
role
ali
whether
effect
also
observ
ard
caus
unknown
time
thu
extrapol
previous
discuss
find
one
may
specul
administr
recombin
product
ang
directli
oppos
ang
ii
may
offer
potenti
benefici
effect
ard
moreov
specif
sar
ard
approach
preclin
studi
ard
specif
due
especi
import
time
bind
may
attenu
residu
activ
tip
balanc
predomin
axi
signal
angii
may
foster
pulmonari
vasoconstrict
inflammatori
oxid
organ
damag
ultim
progress
toward
aliard
specul
raa
dysregul
may
play
central
role
pathophysiolog
tabl
articl
review
evid
relationship
reninangiotensinaldosteron
system
raa
infect
healthcar
profession
physician
research
patient
activ
debat
potenti
influenc
j
u
r
n
l
p
r
e
p
r
f
interstiti
pneumonia
ard
lymphopenia
moreov
observ
surfac
mani
cell
type
heart
kidney
liver
gastrointestin
tract
especi
esophagu
stomach
colon
ileum
rectum
bladder
figur
kuba
et
al
first
show
essenti
sarscov
infect
act
effect
host
receptor
vivo
sarscov
infect
bind
viral
protein
seem
reduc
receptor
express
inject
sarscov
spike
mice
induc
acut
lung
injuri
ali
vivo
mitig
block
raa
wrapp
et
al
recent
report
bind
higher
affin
compar
sarscov
specif
protein
viru
bind
catalyt
domain
induc
intern
viru
cell
brief
raa
central
regulatori
system
bp
control
addit
raa
activ
play
crucial
pathogen
role
htn
hemodynam
action
cytokin
intracellular
signal
pathway
ultim
promot
mani
advers
cellular
process
implic
system
damag
raa
angiotensin
ang
convert
angiotensin
ii
ang
ii
ace
ang
ii
mediat
vasoconstrict
proinflammatori
prooxid
effect
agon
ang
ii
type
receptor
r
convert
ang
ii
angiotensin
final
bind
ma
receptor
masr
mediat
mani
benefici
action
includ
vasodil
antiinflammatori
antioxid
antiapoptot
effect
thu
axi
opposit
action
aceangiiat
r
axi
figur
homologu
ace
integr
cell
membran
protein
catalyt
domain
extracellular
surfac
expos
vasoact
peptid
monocarboxypeptidas
whose
major
role
convert
ang
ii
ang
vasodilatori
antifibrot
action
activ
masr
moreov
also
convert
ang
ang
convert
ace
ang
thu
limit
advers
vasoconstrictor
profibrot
effect
ang
ii
degrad
counteract
action
format
ang
high
express
heart
type
ii
hypothes
increas
level
may
facilit
infect
administ
arb
acei
might
increas
risk
develop
sever
fatal
discuss
later
section
premis
base
part
find
studi
arb
acei
may
increas
level
accord
recent
studi
appear
htn
one
import
factor
associ
poor
prognosi
earli
stage
infect
htn
howev
also
found
associ
decreas
baselin
level
express
unfortun
earli
studi
adjust
age
co
recent
studi
potenti
drug
target
evalu
author
report
arb
eg
irbesartan
may
associ
human
coronavirusesassoci
host
protein
human
interactom
irbesartan
target
gene
solut
carrier
famili
member
interact
gene
potenti
transcript
repressor
interact
nonstructur
protein
sarscov
particip
cov
replic
fidel
crackow
cowork
deshotel
et
al
investig
compensatori
reduct
express
activ
respons
ang
iimedi
htn
elev
level
ang
ii
decreas
activ
cell
surfac
via
rdepend
intern
mechan
moreov
vitro
treatment
cell
ang
ii
enhanc
ubiquitin
also
mediat
r
ultim
stimul
lysosom
degrad
might
prevent
interact
catalyt
site
report
prevent
r
antagonist
losartan
may
block
intern
proteolyt
degrad
ubiquitin
latter
pathway
repres
anoth
mechan
acei
arb
could
prevent
viral
entri
viral
protein
interact
reduc
presenc
stabil
r
complex
arb
could
prove
benefici
stabil
r
interact
prevent
viral
interact
intern
base
mechan
action
gurwitz
recent
suggest
arb
losartan
telmisartan
tent
therapi
patient
prior
develop
aliacut
respiratori
failur
howev
remain
unknown
whether
prevent
intern
would
effect
attenu
infect
sar
coronavirus
studi
urgent
need
clarifi
mechan
interestingli
liu
et
al
report
serum
ang
ii
level
significantli
higher
infect
noninfect
individu
linearli
associ
viral
load
lung
damag
suspect
ang
ii
via
pulmonari
vasoconstrict
lead
decreas
flow
ventilationperfus
mismatch
via
increas
vascular
permeabl
proinflammatori
prooxid
properti
may
induc
perpetu
ard
varieti
patholog
find
liu
et
al
would
support
hypothesi
elev
level
ang
ii
may
foster
ard
patient
nevertheless
studi
import
limit
perform
limit
sampl
requir
confirm
role
raa
peptid
acut
lung
injuri
also
investig
ard
patient
diagnos
within
hour
use
target
metabolom
approach
ang
concentr
significantli
higher
nonsurvivor
studi
entri
hour
ard
surviv
associ
lower
ang
level
higher
ang
concentr
precursor
ang
survivor
show
bind
may
attenu
residu
activ
tip
balanc
predomin
axi
signal
angii
may
foster
pulmonari
vasoconstrict
inflammatori
oxid
organ
damag
ultim
progress
toward
aliard
specul
raa
dysregul
may
play
central
role
pathophysiolog
associ
aliard
definit
studi
address
issu
need
whether
raa
modul
may
benefici
effect
select
patient
sever
risk
aliard
entir
unknown
present
time
moreov
effect
agent
may
interrupt
raa
inhibit
renin
renin
inhibitor
betablock
would
also
interest
regard
effect
attend
ali
agreement
current
guidelin
patient
htn
continu
take
antihtn
medic
prescrib
without
interrupt
current
evid
show
raa
inhibitor
ie
acei
arb
significantli
reduc
mortal
cvd
reduc
progress
ckd
cornerston
hf
htn
treatment
acei
arb
therapi
maintain
initi
indic
patient
hf
htn
myocardi
infarct
regardless
differ
exist
arb
acei
term
efficaci
decreas
bp
improv
outcom
allcaus
mortal
cvd
mortal
myocardi
infarct
hf
stroke
endstag
renal
diseas
acei
associ
cough
secondari
accumul
bradykinin
angioedema
withdraw
rate
due
advers
event
lower
arb
given
equal
efficaci
fewer
advers
event
arb
could
potenti
favor
treatment
option
patient
higher
risk
develop
sever
form
diseas
